Pfizer profit soars in first quarter, revises 2022 forecast

Published May 3, 2022 5:12 am

By TOM MURPHY
AP Health Writer

Sales of Pfizer’s COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61%. The coronavirus vaccine Comirnaty brought in more than $13 billion in sales, and the treatment Paxlovid added another $1.5 billion as company revenue swelled 77%. Overall, Pfizer posted adjusted earnings of $1.62 per share in the first quarter, on $25.66 billion in revenue. FactSet says analysts expected, on average, first-quarter earnings of $1.49 per share on about $24.1 billion in sales. Pfizer also said it was lowering its 2022 earnings forecast to reflect an accounting policy change.

Article Topic Follows: AP National Business

Jump to comments ↓

The Associated Press

BE PART OF THE CONVERSATION

News Channel 3-12 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.